Kane Biotech Presents revyve® Clinical Data at Wound Care Conference

Thermoreversible revyve transforms deep tunneling wound care, delivering 90% wound volume reduction

Apr. 16, 2026 at 1:25pm

Got story updates? Submit your updates here. ›

A ghostly, translucent X-ray photograph revealing the internal structure of a human leg with a deep, tunneling wound. The wound appears as glowing, ghostly lines against a dark background, conceptually illustrating the complex nature of the injury.Innovative wound care technology aims to transform healing for patients struggling with difficult-to-treat chronic wounds.Charlotte Today

Kane Biotech Inc. announced that it presented case study data on how its revyve wound care product can help patients with complex chronic non-healing wounds at the Symposium on Advanced Wound Care (SAWC) Spring conference. The data showed revyve helped reduce wound size by up to 90% and eliminate pain in patients with long-standing venous leg ulcers and deep tunneling wounds.

Why it matters

Chronic wounds are a significant healthcare challenge, often leading to serious complications and high costs. Kane Biotech's revyve product aims to disrupt biofilms, a major contributor to antibiotic resistance in wounds, and transform healing outcomes. The positive clinical data presented at SAWC suggests revyve could provide an innovative solution for patients struggling with difficult-to-heal wounds.

The details

The key data presented by Kane Biotech included:- A patient with >20-year-old venous leg ulcers saw a 40% reduction in wound size after 11 weeks of revyve treatment, with complete elimination of pain by week 6. After 33 weeks, the wound size was reduced by 85%. - A quadriplegic patient with a 1.5-year-old deep tunneling wound switched to revyve and experienced a 90% reduction in wound volume over 7 months, along with significant pain reduction. - Mechanistic studies showed revyve rapidly normalized chronic wound pH from 8.0 to 6.8 in 4 weeks, driving 45-60% wound size reductions.

  • The SAWC Spring conference was held from April 8-12, 2026 in Charlotte, North Carolina.
  • The >20-year-old venous leg ulcer patient saw 40% wound reduction after 11 weeks and 85% reduction after 33 weeks.
  • The quadriplegic patient with a 1.5-year-old deep tunneling wound saw 90% wound volume reduction in 7 months.

The players

Kane Biotech Inc.

A company commercializing and developing novel wound care treatments that disrupt biofilms and transform healing outcomes.

Dr. Miloslav Sailer

The External R&D Leader at Kane Biotech who presented the clinical data at the SAWC Spring conference.

Got photos? Submit your photos here. ›

What they’re saying

“At this year's conference, Kane Biotech shared case study data on how revyve can help patients with complex chronic non-healing as well as clinical mechanistic investigations.”

— Dr. Miloslav Sailer, External R&D Leader, Kane Biotech

What’s next

Kane Biotech plans to continue investigating the clinical efficacy of revyve and pursue further regulatory approvals to make the product available to more patients struggling with difficult-to-heal wounds.

The takeaway

Kane Biotech's revyve product shows promising potential to disrupt biofilms and transform wound care, offering hope for patients with chronic, non-healing wounds that have resisted traditional treatments. The positive clinical data presented at SAWC suggests revyve could provide an innovative solution to a significant healthcare challenge.